[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yefeng\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":5},"100652890","real-world-study-of-the-safety-and-efficacy-of-surufatinib-in-the-treatment-of-neuroendocrine-tumors-100652890",false,"NCT07780539","Real-World Study of the Safety and Efficacy of Surufatinib in the Treatment of Neuroendocrine Tumors","Inclusion Criteria:\n\n* Patients with pathologically or cytologically confirmed neuroendocrine tumors;\n* At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;\n* Life expectancy ≥ 12 weeks;\n* Adequate organ and bone marrow function\n\nExclusion Criteria:\n\n* Participation in other drug clinical trials with investigational drug treatment within the past 4 weeks;\n* History of other malignancies within the past 5 years, except for curatively resected basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ;\n* Patients with contraindications to surufatinib (e.g., active bleeding, ulcer, intestinal perforation, intestinal obstruction, medically uncontrolled hypertension, grade III-IV cardiac dysfunction, within 30 days after major surgery, severe hepatic or renal impairment, etc.);\n* Presence of any disease or condition that affects drug absorption, or inability to take surufatinib orally;\n* Any condition deemed by the investigator as unsuitable for study drug treatment.","ALL","18 Years",{"count":18,"type":19},60,"ESTIMATED","OBSERVATIONAL","Prior clinical trials have demonstrated promising efficacy and manageable safety of surufatinib in neuroendocrine tumors (NETs). This real-world study aims to evaluate the clinical efficacy and safety of surufatinib in patients with NETs, providing additional real-world evidence to support clinical application, guide novel therapeutic strategies, and ultimately improve patient outcomes.",[23],"Neuroendocrine (NE) Tumors","NOT_YET_RECRUITING","2026-08-19",{"date":27,"type":28},"2026-08-21","ACTUAL",{"date":30,"type":19},"2026-09-01",{"date":32,"type":19},"2031-08-31",{"name":34,"class":35},"Yefeng","OTHER",""]